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Background: Poor treatment adherence in COPD patients is associated with poor clinical 
outcomes and increased healthcare burden. Personalized approaches for adherence management, 
supported with technology-based interventions, may offer benefits to patients and providers but 
are currently unproven in terms of clinical outcomes as opposed to adherence outcomes.
Methods: Maximizing Adherence and Gaining New Information For Your COPD (MAGNIFY 
COPD study), a pragmatic cluster randomized trial, aims to evaluate the impact of an adherence 
technology package (interventional package), comprising an adherence review, ongoing provi-
sion of a dual bronchodilator but with an add-on inhaler sensor device and a connected mobile 
application. This will compare time to treatment failure and other clinical outcomes in patients 
identified at high risk of exacerbations with historic poor treatment adherence as measured by 
prescription collection to mono/dual therapy over one year (1312 patients) versus usual care. 
Treatment failure is defined as the first occurrence of one of the following: (1) moderate/severe 
COPD exacerbation, (2) prescription of triple therapy (inhaled corticosteroid/long-acting β2- 
agonist/long-acting muscarinic antagonist [ICS/LABA/LAMA]), (3) prescription of additional 
chronic therapy for COPD, or (4) respiratory-related death. Adherence, moderate/severe exacer-
bations, respiratory-related healthcare resource utilization and costs, and intervention package 
acceptance rate will also be assessed. Eligible primary care practices (N=176) participating in the 
Optimum Patient Care Quality Improvement Program will be randomized (1:1) to either 
adherence support cluster arm (suitable patients already receiving or initiated Ultibro® 
Breezhaler® [indacaterol/glycopyrronium] will be offered interventional package) or the control 
cluster arm (suitable patients continue to receive usual clinical care). Patients will be identified 
and outcomes collected from anonymized electronic medical records within the Optimum Patient 
Care Research Database. On study completion, electronic medical record data will be re- 
extracted to analyze outcomes in both study groups.
Registration Number: ISRCTN10567920.
Conclusion: MAGNIFY will explore patient benefits of technology-based interventions for 
electronic adherence monitoring.
Keywords: adherence monitoring, applications, chronic obstructive pulmonary disease, 
medication adherence, pragmatic randomized clinical trial, technology
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Introduction
Chronic obstructive pulmonary disease (COPD) remains 
amongst the top eight leading causes of disease burden 
worldwide.1 Patients with COPD often experience exacer-
bations and worsening of symptoms, which may result in 
hospitalizations and disease progression.2 Inhaled thera-
pies in COPD have proven to be effective in reducing 
symptoms, frequency and severity of exacerbations, and 
improving quality of life of exacerbating patients.3
Poor adherence to inhaled treatment remains, however, 
a significant problem in COPD patients, often associated 
with worse exacerbation rates and symptom control, 
increased healthcare resources utilization, and reduced 
health-related quality of life.2,4–7 Among COPD patients 
in a clinical setting, mean non-adherence (definition of 
non-adherence varied among studies) to inhaled medica-
tions ranges between 20–60%.4,8–13 Incorrect use and poor 
inhalation technique are also associated with poor disease 
control in such patients,14–16 with the estimated prevalence 
of incorrect inhalation technique ranging between 
14–90%.17 The Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) Report emphasizes the importance 
of adherence and demonstration of proper inhalation tech-
nique to patients with COPD.18 The development of per-
sonalized, data-driven approaches aided by new healthcare 
interventions is expected to play a major role in improving 
medication adherence in such patients through smart inha-
lers, electronic reminders and monitoring.19,20 Recently, 
a connected inhaler system (comprising clip-on inhaler 
sensors, a patient-facing app, and a healthcare professional 
dashboard) was shown to improve adherence to mainte-
nance therapy in patients with respiratory disease; how-
ever, such system did not show an improvement in clinical 
outcomes, possibly due to high adherence in the control 
arm.21 This suggests the need for studies where the control 
arm is maintained as usual care.
Medication adherence assessment remains a challenge 
in clinical research because there is no consistency in the 
methods by which adherence is measured in COPD.22 
Medication adherence rates are usually higher and over-
estimated in randomized clinical trials (RCTs) compared 
with real-world studies.2 This is due to a specific, well- 
defined and highly motivated population, frequent patient 
follow-up, and stringent adherence measures adopted in 
RCTs, very different to a real-life setting where most 
patients may not be interested in or eligible for 
research.23 However, even when medication is beneficial 
in such optimized conditions, variations in adherence are 
associated with major outcomes such as mortality and 
hospital admissions.24 Pragmatic adherence studies can 
mimic clinical scenarios and patients’ natural behavior to 
evaluate whether findings from an RCT can be applied to 
heterogeneous populations in real life.23 Pragmatic RCTs 
imitate routine clinical practice and offer critical evidence 
for decision making by policy-makers, physicians, and 
patients.25
Here, we describe the protocol of the MAGNIFY 
(Maximizing Adherence and Gaining New Information 
For Your COPD) study, an ongoing (ISRCTN10567920), 
pragmatic, cluster RCT. MAGNIFY is the first of its kind 
that aims at evaluating the impact of an adherence technol-
ogy package (interventional package) on time to treatment 
failure and other outcomes in patients with COPD at high 
risk of exacerbations and with historic poor treatment adher-
ence to mono/dual therapy over one year. The intervention 
package includes Ultibro® (indacaterol/glycopyrronium) 
Breezhaler® (Novartis, Basel, Switzerland) with 
a Conformité Européenne (CE) marked add-on inhaler sen-
sor device (add-on device) and app connected mobile appli-
cation. Cluster randomization was preferred to avoid cross 
contamination within practices and keep the trial findings 
relevant for real-world practice by combining real-world 
evidence and randomization and utilizing a heterogeneous 
population to inform treatment effectiveness and healthcare 
decisions.26 Throughout the study, routine care will be 
continued, with no protocol mandated patient visits.
Objectives
The primary objective is to compare the time to treatment 
failure (see below for definition) between patients rando-
mized to receive the intervention package versus those 
receiving usual routine clinical care (control arm). 
Patients will be identified based on their electronic medical 
records and will be randomized to the interventional pack-
age, which comprises an adherence review, ongoing provi-
sion of a dual bronchodilator but with an add-on inhaler 
sensor device and a connected mobile application (adher-
ence support arm [ASA]).
The secondary objectives are to assess: (1) the propor-
tion of patients with at least one moderate/severe exacer-
bation at 12 months and total number of exacerbations at 
12 months based on electronic medical record data, and (2) 
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adherence (based on prescription refill records) over 12 
months.
The exploratory objectives are to assess: (1) respira-
tory-related healthcare resource utilization and costs per 
patient per year, defined by assessing the costs from the 
Optimum Patient Care Research Database, (2) the inter-
vention package acceptance rate at the ASA sites, and (3) 
primary and secondary endpoints, and respiratory-related 
healthcare resource utilization and costs, in the secondary 
and exploratory populations (see Methods section for defi-
nition on different populations), and in the group of 
patients in the ASA versus a subgroup of patients on 
indacaterol/glycopyrronium Breezhaler® (standard) in the 
control and ASA arms.
Methods
Study Design
MAGNIFY is a one-year, pragmatic, cluster randomized, 
multicenter, single-country trial to be run at an estimated 
176 primary care practices in the UK starting 
January 2020. Considering the design and requirements 
of the study, the most efficient option was to perform the 
study in a setting where a single database with integrated 
prescribing data including refill rates and health outcomes 
of interest is available. This could be best obtained only in 
the UK, leading to design the study as a single-country 
trial. The primary care practice is the unit of randomiza-
tion and the practices will be randomized in a 1:1 ratio to 
either the ASA or the control arm27,28 (Figure 1).
Anonymized electronic medical record (EMR) data 
will be used at baseline to identify suitable patients at 
each site prior to the study start. Electronic medical record 
data will then be extracted for defined data analyses in all 
sites on study completion (one year, i.e. 365 days).
To allow feasibility assessment of practices as study 
sites and to collect outcome data, all participating study 
sites will have to participate in the Optimum Patient Care 
(OPC) quality improvement program for COPD.29 OPC 
contributes data to the Optimum Patient Care Research 
Database (OPCRD), a UK based longitudinal electronic 
health record database of over 900 practices and 11 million 
patients with fully characterized chronic disease data. 
From these 900 practices, 176 practices will be selected 
to participate in the study based on their prescribing of the 
appropriate medicines to patients. The patients at practices 
in the ASA arm will get a full COPD quality improvement 
program including the OPC COPD review questionnaire 
and the intervention package, whereas the patients at prac-
tices in the control arm will continue to receive their usual 
routine clinical care. As this is a real-world study with care 
provided by UK physicians, the treatment will not be 
altered. In order to avoid any potential influence that 
administering a questionnaire might have on patient beha-
vior in the control group at the beginning of the study, 
technology acceptance will be evaluated at the end of the 
12-month study period as part of standard COPD review. 
Incorporating questionnaires for control arm at the begin-
ning would also require some feedback to the clinicians. 
This could influence their behavior, thus compromising 
a true “standard of care” comparison.
Trial Participants
Primary Care Practices
Inclusion criteria include practices (1) located in the UK 
(England, Scotland, Wales, Northern Ireland), (2) participat-
ing in the OPC Quality Improvement programs that support 
chronic disease review and in addition, provide high quality 
respiratory data, (3) willing to use advanced technology as 
part of clinical practice, (4) having at least eight patients 
suitable for adherence technology, and (5) actively prescrib-
ing indacaterol/glycopyrronium Breezhaler®. Exclusion cri-
teria include practices not actively prescribing indacaterol/ 
glycopyrronium Breezhaler® to COPD patients as part of 
routine clinical care, and those hosting or affected by 
research, or other aspects of care, which might significantly 
influence the practice-wide implementation.
Optimum Patient Care (OPC) Quality Improvement 
Services
To take part in the study, all practices will have to have 
previously joined the OPC asthma and COPD quality 
improvement service (https://optimumpatientcare.org/qual 
ity-improvement). OPC is a social enterprise providing 
quality improvement since 2005 to over 900 primary 
care practices in the UK (about 1 in 8 practices). 
Pseudonymized data is remotely extracted and analyzed 
and reports generated providing practice level performance 
data and individual patient level data for recommendations 
for management according to national guidance.
Patients
Inclusion criteria include patients aged ≥40 years, ever- 
smokers, on the COPD register of participating practices, 
with coded COPD diagnosis and post-bronchodilator 
forced expiratory volume in 1 second (FEV1)/forced vital 
capacity ever recorded <0.7, with at least two moderate/ 
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severe exacerbations in the last 24 months, and with total 
adherence to current mono/dual therapy of ≤50% based on 
refill pharmacy data in the last 12 months. Exclusion 
criteria include patients with a consent refusal code indi-
cating opt-out of data used for research, those not deemed 
clinically appropriate for the therapy which is technology 
compatible, on triple therapy (ICS/LABA/LAMA), with 
read code for asthma, blood eosinophil count >300 cells/ 
µL (if blood cell count available in the prior 12 months), 
and those unable to use technology (not having/able to use 
a smartphone compatible with the technology, not having 
reliable internet access).
Randomization
Randomization code will be generated via a computer 
code and randomization will be stratified according to 
practice size, deprivation score and the percentage of 
patients with COPD with a record of FEV1 in the preced-
ing 12 months. The data for all three stratification factors 
can be obtained for all National Health Service primary 
care practices through Public Health England (and equiva-
lent for the devolved nations).30 For each factor, median 
value from nationally available data will be used as a cut- 
off to categorize each factor into two strata.
Intervention
Adherence Support Arm (ASA)
In practices randomized to the ASA cluster arm, suitable 
patients already receiving indacaterol/glycopyrronium, or 
initiated on indacaterol/glycopyrronium, will be offered an 
intervention package, i.e. add-on device and a connected 
mobile application (Propeller Health, Wisconsin, USA), 
which have been specifically customized for indacaterol/ 
glycopyrronium. All sites randomized to the ASA will 
receive training from Propeller Health (Wisconsin, USA) 
on the use of the add-on device + app, for the healthcare 
professionals to instruct the patients on the use of this 
technology.
Detailed description of the intervention package can be 
found in the Supplementary File S1.
Control Cluster Arm
Practices randomized to the control arm will continue to 
provide their usual routine clinical care.
Endpoints
The primary endpoint is difference in time (in whole days) 
to treatment failure from baseline to the first occurrence of 
one of the following: (1) moderate/severe COPD exacer-
bation, (2) prescription of triple therapy (inhaled corticos-
teroid/long-acting β2-agonist/long-acting muscarinic 
antagonist [ICS/LABA/LAMA]), (3) prescription of addi-
tional chronic therapy for COPD (theophylline or other 
methylxanthines, maintenance oral corticosteroids, phos-
phodiesterase-4 inhibitors, macrolides, mucolytics or any 
other medication prescribed for COPD), or (4) respiratory- 
related death. An exacerbation is considered moderate/ 
severe exacerbation when the patient requires one of the 
following: (1) an acute oral corticosteroid course 
Figure 1 MAGNIFY trial design. 
Note: It is assumed that 82 practices in each arm will complete the study. 
Abbreviation: EMR, electronic medical record.
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prescription, (2) antibiotics prescribed with evidence of 
a lower respiratory consultation at the same day, (3) 
respiratory-related hospital attendance or admission, or 
(4) respiratory-related accident and emergency/emergency 
room attendance. In the ASA group, the baseline from 
which time to treatment failure will be assessed for each 
patient, is defined as the day of indacaterol/glycopyrro-
nium + add-on initiation following cluster-randomization 
of the site. The median time from cluster-randomization to 
indacaterol/glycopyrronium initiation (i.e. delay) across all 
ASA group sites will be determined. This delay value will 
be added to the time each control practice was cluster- 
randomized, to obtain the baseline timepoint for patients at 
control sites.
The secondary end points include assessment of pro-
portion of patients with moderate/severe exacerbations, 
and total number of exacerbations at 12 months, based 
on electronic medical record data. Adherence will also be 
assessed, determined as Medication Possession Ratio 
(MPR) based on electronic medical record data as follows:
MPR = (Total pack days/observation period in days) * 
100, where,
Total Pack Days = ∑ (Number days per pack), and
Number days per pack = Number of actuations per 
pack/Number of actuations per day.
The exploratory endpoints include assessment of costs 
from the OPCRD for (1) moderate/severe COPD exacer-
bations, (2) respiratory-related primary care consultations, 
(3) respiratory-related outpatient visits, (4) respiratory- 
related accident and emergency attendances, (5) respira-
tory-related hospital admissions, (6) inhalers prescribed, 
mean (SD) and numbers, categorized, (7) other COPD- 
related drugs, (8) number of oral corticosteroid prescrip-
tions, (9) number of acute antibiotic courses with evidence 
of a lower respiratory tract infection. The intervention 
package acceptance rate, defined as the percentage of 
patients who accepted the intervention package, of the 
total number of suitable patients at the ASA sites will 
also be assessed.
Study Visits and Study Assessments
Apart from the intervention initiation visit in the ASA 
practices, there will be no scheduled trial visits, to keep 
the trial closer to the normal clinical practice. All patient 
contacts and visits during the trial will be part of routine 
COPD management and care, in accordance with National 
Institute for Health and Care Excellence 2018 
recommendations.31
Suitable patients in the ASA group will be seen for 
a standard COPD review after the practice has been ran-
domized. At this visit, if the patient is initiated on indaca-
terol/glycopyrronium from a different medication inhaler, 
they will receive indacaterol/glycopyrronium inhaler train-
ing. Patients already on indacaterol/glycopyrronium would 
have their inhaler technique checked as per standard 
COPD review. If the patient accepts the add-on device 
and app, the site practitioner/nurse would assist the patient 
to download the app and register as a user, and to set up 
the add-on device with the inhaler. Patients will be invited 
to use the adherence support system at reviews of their 
COPD. The system consists of an inhaler sensor device 
which is attached to the dual bronchodilator indacaterol/ 
glycopyrronium Breezhaler® and connected to an app on 
the patient’s mobile phone. The sensor was developed and 
manufactured by Propeller Health and is small and 
unobtrusive.20 The patient will be instructed on the use 
of the add-on device and the app and be trained on the 
functionalities of the technology (dose reminders, check-
ing inhaler use statistics, recording COPD control by com-
pleting the COPD Assessment Test and receiving weekly 
COPD digests [can be through email]). Patients will also 
be instructed on the maintenance of the add-on device. 
Suitable patients in the control group will be invited for 
a standard COPD review at 12 months after randomization 
that will include completing an OPC COPD review 
questionnaire.
There will be no study-related assessments. All data 
are either routinely collected, and extracted from primary 
care records, or collected as part of COPD review. No 
additional assessments will be required to collect outcome 
data.
Sample Size Considerations
The sample size was calculated based on existing data 
from over 800 primary care practices within the 
Optimum Patient Care Research Database (OPCRD).32 
Over 5555 patients in the OPCRD were identified as meet-
ing the trial eligibility criteria. Of these, 3010 had outcome 
data available for 1 year and a further 2530 had 
a treatment failure within this outcome period.
For the primary endpoint, assuming that the median 
time to treatment failure in the control arm is 90 days as 
observed on the OPCRD and based on a clinically mean-
ingful increase of 20%33 in the ASA (i.e. 108 days), we 
calculated that 82 practices per arm are required (total 
164). This equates to a hazard in the control arm of 
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0.007 per day and 0.0064 in the ASA, giving a hazard ratio 
of 0.83. Assuming that over 50% of suitable patients 
accept the add-on device and app technology (on average, 
17 suitable patients will be identified at 200 practices to 
qualify as suitable for the trial; of the suitable patients, it is 
estimated that an average of 8 will accept the technology), 
a total sample size of 1312 patients will provide 80% 
power, based on a 5% level of significance and an 
Intraclass Correlation Coefficient (ICC) of 0.038. To 
allow for a practice drop-out rate of approximately 6%, 
88 practices per arm will be enrolled. The ICC was calcu-
lated in the OPCRD dataset of 2530 patients from 508 
practices, using a one-way random effects analysis of 
variance model, with the model fit in Stata V14 (Stata 
Corp, College Station, TX, USA) using the “loneway” 
command specifying “failure time” as the dependent vari-
able, and practice ID as the independent variable.34
Statistical Methods
Analysis Sets
The analysis will be carried out in the primary trial population, 
which is defined to ensure population comparisons are scien-
tifically valid in the ASA and control sites. The study includes 
primary population, secondary population and exploratory 
population, which is described in detail in Table 1.
The following subgroups within each cluster of sites 
will be analyzed: (1) patients on the intervention package 
in the ASA sites and (2) subgroups of patients on indaca-
terol/glycopyrronium in the control sites and ASA sites.
For the primary analysis, time to treatment failure will 
be determined at the individual patient level, with standard 
errors adjusted for clustering of patients within the same 
practice. The primary comparison of trial arms will be 
based on the intention-to-treat principle including all 
patients identified as suitable and accepting of new tech-
nology. Additional details on the analysis, models and 
assumptions are described in Supplementary File S2.
The secondary endpoints will be analyzed in the pri-
mary population. For the adherence endpoint, we will use 
a linear mixed model to compare the mean medication 
possession ratio between the two arms. Random effects 
for the practice and fixed effects for the stratification 
factors used in the randomization algorithm will be 
included in the model. Level of significance will be set 
at 5% for both endpoints. Data will be analyzed in Stata 
V14 (Stata Corp, College Station, TX, USA). Details on 
exploratory and sensitivity analyses are described in 
Supplementary File S3.
Ethics Approval
MAGNIFY trial protocol received approval from the East 
Midlands – Derby Research Ethics Committee on 
November 6, 2019 (REC ref: 19/EM/0238, IRAS: 
260690) and from the UK Health Research Authority 
(December 2, 2019). OPCRD is approved by the Health 
Research Authority for clinical research use and governed 
by the Anonymized Data Ethics & Protocol Transparency 
(ADEPT) Committee (ADEPT0719). The study protocol 
has also been registered with the European Union electro-
nic Register of Post-Authorization Studies (EUPAS 
Register number EUPAS31405). Further details are 
described in the Supplementary File S4. The trial will be 
conducted in accordance with any applicable laws and 
regulations in the UK, and with the Declaration of 
Helsinki.
Sources of Bias
Pragmatic, cluster randomized trials are more exposed to 
biases. Therefore, we have adopted strategies to reduce the 
bias.26,35 The potential sources of bias for MAGNIFY 




ASA site: Group of patients who satisfy inclusion 
criteria at baseline, and accepted the 
intervention package 
Control site: Group of patients who satisfy 
inclusion criteria at baseline and are willing to 
use intervention package (based on COPD 




ASA site: Group of patients satisfying selection 
criteria (i.e. adherence to current mono/dual 
therapy ≤50%) and who were offered the 
intervention package (regardless of their 
acceptance) 
Control site: Group of patients satisfying 
selection criteria (i.e. adherence to current 
mono/dual therapy ≤50%) and continuing with 




ASA site: Group of patients satisfying selection 
criteria (i.e. adherence to current mono/dual 
therapy ≤50%) and who accept or do not accept 
the technology
Abbreviations: ASA, adherence support arm; COPD, chronic obstructive pul-
monary disease; ICS, inhaled corticosteroids; LABA, long-acting beta-2 agonists; 
LAMA, long-acting muscarinic antagonists.
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include index date, treatment failures and impact on pre-
scribing decisions. The description for the sources and the 
measures taken to address these, are described in Table 2.
Discussion
Medication non-adherence is a global, complex and multi-
factorial challenge.36 Health interventions that aim at 
improving it are often not properly evaluated. Considering 
this, we have designed a pragmatic cluster randomized trial, 
MAGNIFY, to investigate the impact of a technology-based 
medication adherence approach in exacerbating COPD 
patients with poor adherence to mono/dual therapy.
The MAGNIFY study offers opportunities to capture 
patient medication adherence details in a real-life scenario. 
Cluster randomized trials generally include a broader 
range of patients and trial sites (by including community- 
based, non-academic sites), and can evaluate outcomes 
that are aligned with the evidence needs of decision- 
makers (e.g. patients, clinicians, payers, and policy- 
makers).37 These trials are well-suited for providing 
evidence on effectiveness of clinical interventions, such 
as electronic monitoring, in real-world practice.38 Notably, 
they minimize the risk of cross contamination between 
intervention and control group patients within the same 
practice. Pragmatic study design sets the study in real 
clinical practice as far as possible. With the widespread 
use of electronic health records, there are increasing 
opportunities to integrate pragmatic cluster trial designs 
with real-world datasets to improve patient safety, data 
accuracy, and clinical trial efficiency.
Various approaches are being considered to monitor 
medication adherence because improving adherence to 
therapy has shown substantial health and economic 
benefits.39 A personalized treatment approach aided with 
digital inhaler technologies is one such approach.19,40 
Technology-enabled inhalers offer a range of support 
such as patient reminders, feedback on inhaler technique 
and timing, and sensors to analyze inspiratory flow rates, 
and characterize inhaler technique.19,40 Another novel 
technology-driven approach to improve adherence and 
Table 2 Potential Sources of Bias and Measures to Address Bias
Potential Source of Bias Measures Taken to Address Bias
Index date
Date of initiation on the adherence package is used as the index date in 
the ASA patients, but there is no equivalent index date in the control 
arm. The median time from cluster randomization to the package 
initiation (i.e. delay) across all adherence support group sites will be 
determined and this delay value will be added to the time each control 
practice was cluster randomized, to obtain the follow-up period start 
date (“index date”) for patients at control sites. This approach ensures 
that the baseline is time-matched between the two arms, but may cause 
bias because in the control arm the index date is not defined on 
a patient-level as it is in the ASA
Sensitivity analyses will be conducted using: 
(a) the first COPD maintenance treatment after practice randomization 
as the index date in the control arm, and 
(b) the first primary care practitioner consultation after practice 
randomization as index dates in the control arm
Treatment failures
Stepping up maintenance therapy is often considered as a treatment 
failure in clinical studies. However, if any maintenance therapy step up 
was considered a treatment failure, there would be potential bias for 
more treatment failures in the control arm due to patients on 
monotherapy being stepped up to LABA/LAMA or ICS/LABA (both in 
line with current treatment recommendations), while in the ASA 
initiation on the package (LABA/LAMA) at baseline of a patient 
previously on monotherapy cannot be considered a treatment failure
Only step up to triple therapy will be considered treatment failure in the 
primary analysis. However, a sensitivity analysis will be conducted using 
a modified definition of the primary outcome where any step up is 
considered a treatment failure
Impact on prescribing decisions
Participation in the trial may drive LABA/LAMA prescribing decisions at 
participating sites
Only sites that are actively prescribing LABA/LAMA will be included in 
the trial. LABA/LAMA is recommended for patients with COPD by the 
current treatment guidelines
Abbreviations: ASA, adherence support arm; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting beta-2 agonists; LAMA, long- 
acting muscarinic antagonists.
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patient behavior is by using a smartphone app.41 The 
advantage with this approach is that it is constantly acces-
sible, involves and educates the patient, and provides 
a repository for patient- and medication-specific informa-
tion. A smartphone medication adherence-oriented app 
(adherence apps) can potentially consolidate all of the 
user’s medication-specific information and thereby pro-
vide a more streamlined process to educate the individual 
about their disease.41 Compared with traditional 
approaches, technology-based approaches for medication 
adherence can reduce the cost and effort from the patient 
and caregiver’s perspective. Additionally, the accuracy of 
the adherence measure, which is of great importance from 
the healthcare provider’s point of view, can be enhanced 
using electronic-based systems.39 Therefore, in 
MAGNIFY, using an intervention package, a dual bronch-
odilator with an add-on inhaler sensor device and con-
nected mobile app, offers enhanced adherence support 
benefits to patients with COPD in managing 
exacerbations.
Following the CONSORT statement guidelines for 
pragmatic cluster randomized trials, we ensured that the 
risk of contamination as a result of selection bias with 
preference of patient or physician will be minimized.27 
The correct intervention according to COPD treatment 
guidelines for these patients is to address adherence and 
inhaler technique, not to step up therapy.18
Conclusion
We have described in detail the novel study design of the 
MAGNIFY trial. Positive outcomes from this pragmatic clus-
ter randomized trial will provide real-life evidence on whether 
usage of technology-aided adherence support in combination 
with indacaterol/glycopyrronium Breezhaler® can be benefi-
cial in patients with COPD, and whether it is cost-effective in 
usual practice. The results from this study will inform future 
approaches to improve adherence, offering the potential to 
improve patient outcomes and reduce healthcare costs.
Abbreviations
ASA, adherence support arm; COPD, chronic obstructive 
pulmonary disease; CE, Conformité Européenne; EMR, 
electronic medical record; FEV1, forced expiratory volume 
in 1 second; GOLD, Global Initiative for Chronic 
Obstructive Lung Disease; ICC, Intraclass Correlation 
Coefficient; ICS, inhaled corticosteroids; LAMA, long- 
acting muscarinic antagonists; LABA, long-acting β2 ago-
nists; MPR, medication possession ratio; OPCRD, 
Optimum Patient Care Research Database; OPC, 
Optimum Patient Care; RCTs, randomized clinical trials; 
TAP, technology adherence package.
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